Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Ранг среди акций #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Цена акции
$0.07339369
Последняя синхронизация: 2026-08-18
Рыночная капитализация
$25.24M
Изменение (1 день)
5.26%
Изменение (1 год)
-7.44%
Страна
CA
Торговля Resverlogix Corp. (RVX)

Категория

Коэффициент P/B для Resverlogix Corp. (RVX)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Resverlogix Corp., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Resverlogix Corp. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH